Seeking Alpha

Carlyle to buy J&J's diagnostics unit for $4.15B

  • Carlyle (CG) confirms that it has agreed to acquire Johnson & Johnson's (JNJ +0.3%) Ortho-Clinical Diagnostics (OCD) business for $4.15B.
  • "This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson," J&J CEO Alex Gorsky says.
  • OCD provides products for screening, diagnosing, monitoring and confirming diseases, including blood-screening equipment and laboratory blood tests. It's a smallish player in a market led by Roche, Siemens and Abbott Labs. (PR)
This was corrected on 01/16/2014 at 08:12 AM.
Comments (1)
  • psittner
    , contributor
    Comments (19) | Send Message
    I see you correctly removed ConAgra's ticker and put in the right one, but this is still showing up under CAG's updates. May want to make an update there, fellas.
    16 Jan, 09:55 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: